Clinical trials: irinotecan hydrochloride
Pancreatic Cancer
Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
This is a prospective, single arm, single center, phase II study of cadonilimab plus mFOLFIRINOX as conversion therapy in patients with locally advanced pancreatic cancer.
- Trial name
- NCT06153368
- Testing
- Cadonilimab+mFOLFIRINOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Adenocarcinoma, Stage II Gastric Cancer
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction.
- Conditions
- Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
- Trial name
- NCT00062374
- Testing
- Cisplatin, Computed Tomography, Fludeoxyglucose F-18
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Liver Metastases (CRCLM)
To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases
Both drug-eluting bead transarterial chemoembolization (DEB-TACE) and hepatic arterial infusion chemotherapy (HAIC) are recommended for unresectable colorectal liver metastases (CRLM) treatment.
- Trial name
- NCT05889325
- Testing
- DEB-TACE plus HAIC
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Intrahepatic Cholangiocarcinoma (Icc)
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (ICC), the second most prevalent primary malignant liver neoplasm, features highly aggressive biological behavior and dismal prognosis.
- Trial name
- LPHAIC for ICC (NCT07646717)
- Testing
- hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
The purpose of this study is to determine the efficacy of an oral investigational drug in patients with refractory metastatic colorectal cancer after receiving prior therapy with 5-fluorouracil in combination with irinotecan…
- Trial name
- NCT00044343
- Testing
- lapatinib
- Where
- 57 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Metastatic Colorectal Cancer
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
The purpose of this study is to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an…
- Trial name
- AFEMA (NCT03279289)
- Testing
- Aflibercept, Irinotecan, folinic acid (dl racemic)
- Where
- Spain
- Volunteers
- 170 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Gastro-Oesophageal Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
- Trial name
- INTEGRATEIIb (NCT04879368)
- Testing
- Regorafenib, Nivolumab, Docetaxel
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 462 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Nanoliposomal Irinotecan, Cadonilimab
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal…
- Conditions
- Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin, Capecitabine
- Trial name
- NCT06405490
- Testing
- Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis
5-Fuorouracil (5-Fu) remains one of the most effective and most commonly used drugs to treat colorectal cancer. Mucositis is a major complication that occurs in approximately 80% of patients receiving 5-FU and results in…
- Trial name
- NCT04151355
- Testing
- Atorvastatin 20mg
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Unspecified Adult Solid Tumor, Protocol Specific
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006485
- Testing
- alvocidib, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00423696
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- 15 sites in France
- Volunteers
- 145 people
- Sponsor
- UNICANCER
Colorectal Cancer
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether fluorouracil and leucovorin plus irinotecan is more effective than fluorouracil…
- Trial name
- NCT00004885
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 57 sites in Austria, Belgium and 7 more
- Volunteers
- 430 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Small Cell Lung Cancer Extensive Stage
Liposomal Irinotecan and Apatinib in ES-SCLC
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
- Trial name
- LIAES (NCT06749691)
- Testing
- Liposomal Irinotecan and Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer
Cetuximab Monotherapy Maintenance Treatment in mCRC
Investigating the efficacy of Cetuximab Monotherapy versus Continuation after induction treatment with chemotherapy + Cetuximab in inoperable or irresectable and non-progressive metastatic colorectal cancer after first line…
- Trial name
- NCT02978313
- Testing
- Cetuximab, mFOLFOX6, FOLFIRI
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Esophageal Cancer
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00109850
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- 132 sites in United States
- Volunteers
- 22 people
- Sponsor
- SWOG Cancer Research Network
Gastrointestinal Neoplasm, Gastric Adenocarcinoma
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
The investigators hypothesize IXO chemotherapy will have an improvement in response rate and acceptable toxicity for uncurable metastatic gastric cancer compared to historical controls.
- Trial name
- IXOGoo1 (NCT01129310)
- Testing
- Irinotecan-Capecitabine-Oxaliplatin
- Where
- Canada
- Volunteers
- 47 people
- Sponsor
- AHS Cancer Control Alberta
Pancreatic Cancer Resectable, Pancreatic Cancer Stage II
Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer
The goal of this observational retrospective cohort study is to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAT) in elderly patients with resectable or borderline resectable (BR) pancreatic ductal adenocarcinoma…
- Conditions
- Pancreatic Cancer Resectable, Pancreatic Cancer Stage II, Neoadjuvant Therapy, Elderly
- Trial name
- PEACE (NCT06868693)
- Testing
- Neoadjuvant Chemotherapy (NAT) Group
- Volunteers
- 240 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Phase 2 Study
mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer
Neoadjuvant mFOLFOXIRI plus bevacizumab may achieve tumor shrinkage and reduce micrometastases, offering a radiotherapy-free organ-preservation alternative for locally advanced rectal cancer.
- Trial name
- FOBEAR-ii (NCT07817888)
- Testing
- FOLFOXIRI + Bevacizumab
- Volunteers
- 119 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Pancreatic Cancer Metastatic
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
A prospective, multicenter, open label, randomized phase III study to evaluate efficacy and safety of FFX versus CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years
- Trial name
- NCT03504423
- Testing
- CPI 613, mFolfirinox, Folfirinox
- Where
- 74 sites in United States, Belgium and 4 more
- Volunteers
- 528 people
- Sponsor
- Cornerstone Pharmaceuticals
Metastatic Colorectal Cancer
A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer
Triplets of irinotecan, oxaliplatin and infusional 5-fluorouracil(FU)/leucovorin (LV) are associated with high response rates and long survival as first-line treatment for metastatic colorectal cancer (mCRC).
- Trial name
- IXO+A (NCT00819754)
- Testing
- IXO regimen + bevacizumab
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Ottawa Hospital Research Institute